|
advertisement
|
Company Overview: |
Alnylam Pharmaceuticals is a biopharmaceutical company that is developing new therapeutic products based on a biological breakthrough called RNA interference (RNAi) which opens up a whole new realm of possibilities for a broad classifcation of human therapeutics. Annylam has used its RNA interference process to create a product platform that will be used to develop drugs that will be used to fight all manner of diseases.
Furthermore, Alnylam is developing technology that has the potential to single out and neutralize disease-causing genes. RNA interference is a natural cellular process that is being harnessed by the scientists of Alnylam and then used in the formulation of its various therapeutic product lines. The RNAi selectively turns off the activity of genes by targeting RNA, which is an intermediate element in genetic structure between DNA and proteins. In this way, by having control over this process, the company can target different genes which produce proteins which can have harmful effects within some diseases and shut them off.
Alnylam has assembled an experienced management team, strong financial resources, and world class collaborators to build a pipeline of RNAi therapeutics using both Direct RNAi and Systemic RNAi approaches. Various patents and patent applications have been established to provide broad coverage to the compositions, methods and uses of small interfering RNAs (or siRNAs which are the molecules that mediate RNAi). It operates from two facilities: Alnylam Pharmaceuticals of Cambridge, Massachusetts, and Alnylam Europe of Kulmbach, Germany. Alnylam has formed major alliances with Merck, Medtronic and Novartis. It is also currently has licenses to numerous companies for both therapeutic as well as research market applications.
|
Products and Services: |
Alnylam Pharmaceuticals is devoted to creating various product applications with its understanding of RNAi. By understanding how genes can be turned on and off in cells, a whole new approach to drug concepts and development is made available. There is unlilmited potential if the properties of this natural process can be drawn from and formulated. These RNAi therapeutic products are designed to specifically target the root or base genetic cause of diseases. This is done by silencing specific messenger RNA, which will prevent disease-causing proteins from being produced and causing problems with DNA.
Respiratory Syncytial Virus (RSV)
ALN-RSV01 is Alnylam's lead development program. RSV infection poses a great risk to young children and other immune compromised groups including the elderly and those undergoing bone marrow transplants.
Pandemic Flu
The company has an influenza program that is trying to develop Direct RNAi therapeutics that are effective against all flu strains including potentially highly virulent strains of flu, such as H5N1.
Spinal Cord Injury (SCI)
Alnylam and Merck have initiated a pre-clinical program to develop RNAi therapeutics for spinal cord injury.
Parkinson's Disease (PD)
Alnylam's Direct RNAi program for Parkinson’s that aims to block production of alpha-synuclein, a protein thought to be the potential cause of PD and one that cannot feasibly be targeted using existing classes of drugs.
Cystic Fibrosis (CF)
The Cystic Fibrosis Foundation Therapeutics (CFFT) and Alnylam are collaborating to discover Direct RNAi therapeutics for the treatment of the genetic disease Cystic Fibrosis.
Neuropathic Pain
Alnylam's proprietary program is focused on developing an RNAi therapeutic to treat neuropathic pain by targeting NaV1.8, a gene that encodes an ion channel believed to play a important role in chronic neuropathic pain.
Hypercholesterolemia
Alnylam is collaborating with researchers at UT Southwestern Medical Center to evaluate new approaches for reducing LDL-cholesterol levels using RNAi therapeutics directed to a disease target called PCSK9.
Progressive Multifocal Leukoencephalopathy (PML)
Alnylam and Biogen Idec are partnering to research potential use of RNAi technology to discover and develop therapeutics to treat the CNS disorder Progressive Multifocal Leukoencephalopathy or PML.
|
Key Personnel Facts: |
John K. Clarke: Chairman
John M. Maraganore: President, Chief Executive Officer, and Director
Barry E. Greene: Chief Operating Officer
Employees (2005): 94
1-Year Employee Growth: 32.4% |
Key Financial Facts: |
Fiscal Year-End: December
Sales (2005): $5.7M
1-Year Sales Growth: 33.6%
Net Income (2005): $42.9M
|
Back to Top
|
|
Working @ Alnylam Pharmaceuticals
Have your shout about working or interveiwing at Alnylam Pharmaceuticals
1 message posted
Message Posted:
Working @ Alnylam Pharmaceuticals, Inc.
Share your experiences about working, interviewing or applying for a job at Alnylam Pharmaceuticals, ...
Author: Obi Posted: 3/2/2007 3:24:47 PM |
View or add comments about Alnylam Pharmaceuticals
Back to Top
|
Alnylam Pharmaceuticals in the News
- Alnylam Pharmaceuticals Soars on Roche Holding Collaboration (Seeking Alpha)
Published: Tuesday, July 10, 2007
- Sequa Cl A, Alnylam Pharmaceuticals: Biggest Price Gainers (SQAA, ALNY) (at The Wall Street Journal Online)
Published: Monday, July 09, 2007
- Press Release: Roche Holding and Alnylam Pharmaceuticals Form $1 Billion Alliance on RNAi Therapeutics
Published: Monday, July 09, 2007
- Roche signs alliance deal with Alnylam Pharmaceuticals (at MarketWatch)
Published: Monday, July 09, 2007
- Isis Pharmaceuticals Expects to Earn Initial Payments of Nearly $4 Million From Alnylam's Recent RNAi Collaboration
Published: Monday, September 12, 2005
View more news about Alnylam Pharmaceuticals
Back To Top |
|
Alnylam Pharmaceuticals Journal Citations
View more Alnylam Pharmaceuticals journal citations
Back To Top |
|
|
Categories:
|
Biotechnology
|
|
Back to Top
|
|
|
|